Literature DB >> 5441787

Changes in the molecular composition of circulating hydroxyethyl starch.

S P Farrow, M Hall, C R Ricketts.   

Abstract

1. Hydroxyethyl starch (HES) of molecular weight 450,000 has been extensively investigated as a plasma volume expander and HES of molecular weight 60,000 has been proposed for use as a cryoprotective agent in the freezing for preservation of red blood cells. In these applications considerable amounts of HES may be injected intravenously and it is therefore desirable to understand its behaviour in vivo.2. After intravenous injection into rabbits, plasma levels of HES and clinical dextrans were determined using anthrone. HES persisted longer in the circulation than did the dextrans.3. HES was recovered from the bloodstream of rabbits and shown by gel filtration to be of a narrower molecular size distribution than the injected material. Smaller molecules were removed, presumably by filtration at the glomerulus. Larger molecules may have been removed by cells of the reticuloendothelial system or possibly through the action of amylase.4. The amylase in saliva was shown to break down HES into molecules of intermediate size with very little production of maltose units.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5441787      PMCID: PMC1702592          DOI: 10.1111/j.1476-5381.1970.tb09880.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  Clinical evaluation of a new plasma expander hydroxyethyl starch.

Authors:  W H Lee; N Cooper; M G Weidner; E S Murner
Journal:  J Trauma       Date:  1968-05

2.  Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander).

Authors:  T F Solanke
Journal:  Br Med J       Date:  1968-09-28

3.  Use of hydroxyethyl starch solution in extensive surgical operations.

Authors:  S Gollub; D C Schechter; T Hirose; C P Bailey
Journal:  Surg Gynecol Obstet       Date:  1969-04

4.  Is there a common mechanism of protection of living cells by polyvinylpyrrolidone and glycerol ding freezing?

Authors:  J Farrant
Journal:  Nature       Date:  1969-06-21       Impact factor: 49.962

5.  Preliminary report on the use of hydroxyethyl starch solution in man.

Authors:  W F Ballinger; G F Murray; E E Morse
Journal:  J Surg Res       Date:  1966-04       Impact factor: 2.192

6.  Molecular composition of transfusion dextran. A report to the Medical Research Council's Blood Transfusion Research Committee.

Authors:  C R Ricketts
Journal:  Br Med J       Date:  1966-12-10

7.  Hydroxyethyl starch: extracellular cryophylactic agent for erythrocytes.

Authors:  C T Knorpp; W R Merchant; P W Gikas; H H Spencer; N W Thompson
Journal:  Science       Date:  1967-09-15       Impact factor: 47.728

8.  PLASMA VOLUME EXPANSION BY RAPID INFUSION OF A LOW MOLECULAR WEIGHT DEXTRAN.

Authors:  J W DAVIES; C R RICKETTS; B N WILLIAMS
Journal:  Br J Pharmacol Chemother       Date:  1963-10
  8 in total
  4 in total

1.  Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-09       Impact factor: 3.411

2.  Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-02       Impact factor: 3.411

3.  Changes in the molecular composition of circulating hydroxyethyl starch following consecutive daily infusions in man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  Br J Clin Pharmacol       Date:  1979-05       Impact factor: 4.335

4.  Hydroxyethyl starch. An agent for hypovolaemic schock treatment II. Urinary excretion in normal volunteers following three consecutive daily infusions.

Authors:  J M Mishler; H Borberg; P M Emerson; R Gross
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.